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Purpose: Diabetic retinopathy (DR) is a leading cause of vision loss and blindness among adults between the age 20 to
74. Changes in ionotropic glutamate receptor subunit composition can affect retinal glutamatergic neurotransmission and,
therefore, contribute to visual impairment. The purpose of this study was to investigate whether diabetes leads to changes
in ionotropic glutamate receptor subunit expression at the protein and mRNA level in the rat retina.
Methods: Changes in the expression of ionotropic glutamate receptor subunits were investigated at the mRNA and protein
levels in retinas of streptozotocin (STZ)-induced diabetic and age-matched control rats. Animals were euthanized one,
four and 12 weeks after the onset of diabetes. Retinal protein extracts were prepared, and the receptor subunit levels were
assessed by western blotting. Transcript levels were assessed by real-time quantitative PCR.
Results: Transcript levels of most ionotropic glutamate receptor subunits were not significantly changed in the retinas of
diabetic rats, as compared to age-matched controls but protein levels of α-amino-3-hydroxyl-5-methyl-4-isoxazole-
propionate (AMPA), kainate, and N-methyl-D-aspartic acid receptors (NMDA) receptors were found to be altered.
Conclusions: The results provide evidence that diabetes affects the retinal content of ionotropic glutamate receptor
subunits at the protein level. The possible implications of these changes on retinal physiology and visual impairment in
DR are discussed.
Diabetic retinopathy (DR) is a leading cause of vision loss
and blindness among adults in developed countries. The
mechanisms by which diabetes causes vision loss are still not
clearly understood. Vascular changes in DR are well
documented, and include blood-retinal barrier breakdown,
loss of pericytes and endothelial cells, the formation of
microaneurysms and basement membrane thickening [1].
Changes in the neural retina during diabetes have also been
reported [2-4]. These alterations may account for loss in
contrast sensitivity and color vision and alterations in the
electroretinogram [5-8].
Glutamate is the main excitatory neurotransmitter in the
retina. It is required for the transmission of visual signals from
the photoreceptors to the ganglion cells. Glutamate receptors
are divided into two main groups: the fast-acting ligand-gated
ionotropic channels and the slower-acting metabotropic
receptors. The ionotropic receptors are cation-specific ion
channels, and are subdivided into three groups: α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionate (AMPA), kainate,
and N-methyl-D-aspartate (NMDA) receptor channels. In the
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mammalian retina, AMPA, kainate, and NMDA receptor
subunits have been shown to have a widespread and
differential distribution throughout the retina [9-14].
Several studies have indicated that diabetes induces
changes in glutamate receptors. The ob/ob mouse, a model of
type 2 diabetes, was found to have increased binding sites for
NMDA and AMPA receptors in the gray matter of the spinal
cord [15]. In the brain of streptozotocin (STZ)-induced
diabetic rats, the binding properties of AMPA receptors and
the expression of GluR1 subunit are decreased [16], without
changes in the transcript levels of GluR1, GluR2/3, NR1, and
NR2A subunits after three months of diabetes [17]. In the
hippocampus, immunoreactivity for NR2A and NR2B
subunits are reduced in diabetic rats. These changes are
prevented by insulin treatment [18,19]. Additionally,
glutamatergic dysfunction in the hippocampus has been
suggested to be associated with cognitive impairment in the
STZ-induced diabetic rat [20]. Moreover, it was reported that
the transcript levels for GluR1, GluR2, GluR3, NR2A, and
NR2B subunits are significantly upregulated in the dorsal
horn of the spinal cord in STZ-induced diabetic rats [21].
Overactivation of glutamate receptors is considered to be
potentially involved in neurodegeneration in some retinal
diseases, such as glaucoma and retinitis pigmentosa [22,23],
and it may be also implicated in retinal neurodegeneration
during diabetes. In the retina, it was shown that glutamate
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metabolism and concentration are altered after short-term
experimental diabetes. Diabetic rat retinas are less able to
convert glutamate into glutamine [24] and have higher levels
of glutamate [25], probably explaining increased vitreous
glutamate concentration observed in patients with
proliferative DR [26]. Moreover, the high-affinity L-
glutamate/L-aspartate transporter (GLAST) is impaired in
retinal Müller cells isolated from STZ-induced diabetic rats,
probably due to oxidation of the glutamate transporter [27].
Previously, we demonstrated that diabetes increases the
evoked release of D-aspartate in the retina [28], suggesting
that glutamatergic neurotransmission can be affected in the
retinas of diabetic rats. Moreover, we showed that elevated
glucose concentration changes the protein levels of GluR1,
GluR2, GluR6/7, and KA2 subunits in cultured rat retinal
neural cells [29], and more recently, we have demonstrated,
in postmortem human retinas, that there are alterations in the
levels of ionotropic glutamate receptor subunits in diabetic
patients [30]. It was also demonstrated an increase in NR1 and
GluR2/3 immunoreactivities in ganglion, amacrine, and
bipolar cells in rats after 4 and 16 weeks of diabetes [31].
Taken together, these results support a role for glutamate
in the pathogenesis of DR, suggesting that it may be involved
in retinal neural dysfunction during diabetes. Changes in the
composition of ionotropic glutamate receptor subunits may
alter the properties of ionotropic glutamate receptors, and
consequently may change the glutamatergic
neurotransmission in the retina, thus contributing to visual
impairment. In addition, those changes may alter the
vulnerability of retinal neurons to neurodegeneration. Thus,
the aim of this work was to investigate whether diabetes
changes ionotropic glutamate receptor subunits in the retina
at mRNA and protein levels.
METHODS
Animals: All procedures involving animals were conducted in
accordance with the Association for Research in Vision and
Ophthalmology (ARVO) statement for the use of animals in
ophthalmic and vision research. Two-month-old Wistar rats
purchased from Charles River (Barcelona, Spain) were
housed under a 12 h light/12 h dark cycle with standard chow
and water ad libitum. Animals were randomly assigned to
control or diabetic groups. Diabetes was induced with an
intraperitoneal injection of 65 mg/kg STZ (Sigma, St. Louis,
MO), dissolved in citrate buffer, pH 4.5. Two days post-STZ
injection, hyperglycemia was confirmed by blood glucose
exceeding 250 mg/dl with Ascensia Elite (Bayer, Portugal).
Diabetic rats and age-matched controls were euthanized under
deep anesthesia followed by decapitation, one, four, and 12
weeks after the onset of diabetes. Before sacrifice, rats were
weighed and blood glucose was measured.
Sample preparation for western blot analysis: Each sample
was composed of both retinas from the same animal
(n=number of animals). The animals were euthanized, the
eyes were enucleated, and the retinas were dissected in cold
phosphate-buffered saline (PBS) that contained 137 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH
7.4. The retinas were then homogenized in 20 mM Tris-HCl,
2 mM EDTA, 2 mM EGTA, pH 7.2, supplemented with
complete miniprotease inhibitor cocktail tablets (Roche,
Basel, Switzerland), at 4 °C. The homogenate was centrifuged
at 960x g for 5 min at 4 °C. The supernatant was collected and
centrifuged at 15,800x g for 20 min at 4 °C. The pellet was
dissociated by sonication and resuspended in 20 mM Tris-
HCl, 2 mM EDTA, 2 mM EGTA, 1% Triton X-100, 0.5%
SDS, pH 7.2, supplemented with the protease inhibitor
cocktail, at 4 °C. Protein concentration was determined by the
Bio-Rad Bradford method, and the samples were denaturated
following addition of 2X concentrated sample buffer, which
contained the following: 100 mM Tris-HCl:100 mM bicine,
8 M urea, 2% SDS, 2% β-mercaptoethanol, 0.005%
bromophenol blue. After heating for 5 min at 95 °C, the
samples were frozen at −20 °C until western blot analysis.
Western blot analysis: Equivalent amounts of protein (15 μg
for GluR1, GluR6/7, and NR1 subunits; and 60 μg for GluR2,
GluR2/3, GluR4, NR2C and NR3A subunits) were used for
western blot analysis. The amounts of protein used were under
the saturation limit of the system.
Proteins were separated by SDS–PAGE (7.5%), and
transferred via electrophoresis to polyvinylidene fluoride
(PVDF) membranes. The membranes were blocked for 1 h at
room temperature in Tris-buffered saline that contained
137 mM NaCl, 20 Tris-HCl mM, pH 7.6, with 0.1% Tween-20
(TBS-T) and 5% skimmed milk. Incubation with the primary
antibodies (Table 1) was performed overnight at 4 °C. After
washing four times during 1 h in TBS-T in TBS-T with 0.5%
skimmed milk, the membranes were incubated for 1 h at room
temperature with 1:20,000 anti-rabbit IgG (GE Healthcare,
Buckinghamshire, UK), an alkaline phosphatase-linked
secondary antibody, in TBS-T with 1% skimmed milk. The
membranes were processed for detection of ionotropic
glutamate receptor subunits using the Enhanced Chemi-
Fluorescence system (GE Healthcare) on a gel imager (Versa
Doc Imaging System; Bio-Rad, Hercules, CA), and digital
quantification of bands intensity was performed (Quantity
One; Bio-Rad).
The membranes were then reprobed and tested for α-
tubulin (Sigma-Aldrich, Lisboa, Portugal), which was used as
a loading control. Briefly, the membranes were incubated for
1 h at room temperature with a 0.1 M glycine buffer (pH 7.2),
blocked as previously described and then incubated with
1:3,000 mouse anti-α-tubulin antibody (Sigma). The
membranes were then washed and incubated with 1:20,000
anti-mouse IgG (GE Healthcare), an alkaline phosphatise-
linked secondary antibody in TBS-T with 1% skimmed milk.
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Isolation of total RNA from rat retinas—Each sample
was composed of one retina (n=number of animals). The
animals were euthanized, the eyes were enucleated, and the
retinas were dissected in cold PBS and stored at −80 °C.
Retinal tissue was homogenized, and total RNA was isolated
by a single-step method, based on guanidine thiocyanate
extraction, according to the manufacturer’s instructions
(Ultraspec; Biotecx Laboratories, Inc., Houston, TX). Isolated
RNA was dissolved in 16 µl diethylpyrocarbonate (DEPC)-
treated water. The concentration and quality of total retinal
RNA were determined (2100 Bioanalyser; Agilent
Technologies Netherlands BV, Amstelveen, The
Netherlands). The integrity of RNA, expressed as RNA
Integrity Number (RIN) was around 9.0, indicating, high-
quality, non-degraded RNA.
Reverse transcription—Total RNA was treated with
DNase-I (1 unit DNase-I, Amplification Grade; Invitrogen
BV, Breda, The Netherlands) to degrade possible genomic
DNA contamination. Then, 5 μl of Dnase-I treated total RNA
were reverse transcribed into first-strand cDNA with 100 U/
μl of RNase H- reverse transcriptase (Superscript III,
Invitrogen) and 50 ng/μl random hexamer primers, for 60 min
at 50 °C. The resultant cDNA sample was diluted 1:1 with
100 mM Tris and 1 mM EDTA, and from all cDNA samples
a 1:20 dilution was prepared for qPCR analysis [32]. All
samples were stored at −20 °C until analysis.
Genomic DNA contamination was assessed with a
conventional end point PCR for β-actin, using intron-
spanning primers, under the following conditions: annealing
at 55 °C, elongation at 72 °C, denaturing at 94 °C, 90 s each
step for 35 cycles, with 1.5 mM Mg2+ and 0.75 U Taq DNA
polymerase (Qiagen, Westburg, The Netherlands). The
resultant PCR product was analyzed by agarose gel
electrophoresis. A single band of the anticipated exon-size
was found in all samples, demonstrating the absence of
genomic contamination. Nontemplate and nonamplicon
controls were subjected to PCR amplification, but they never
yielded PCR products.
qPCR primers—qPCR primer pairs were designed
using Primer Express V 2.0 software (PE Applied Biosystems,
Warrington, UK). Details of the primers and the GenBank
Accession numbers are given in Table 2.
Real-time quantitative PCR—Real-time qPCR is based
on the real-time monitoring of fluorescent SYBR Green I
(Prism 5700; Applied Biosystems Inc., Nieuwekerk a/d IJssel,
The Netherlands). The qPCR conditions were as follows: 1×
SYBR Green PCR buffer; 3.5 mM MgCl2; 200 µM dATP,
200 μM dGTP, and 200 μM dCTP, and 400 µM dUTP; 0.5 U
Taq polymerase (AmpliTaq Gold; Applied Biosystems); 0.2
U uracil-N-glycosylase (UNG; AmpErase; Applied
Biosystems), 2 pmol primers; and 2 µl of the 1:20 dilution of
cDNA in a total volume of 20 µl. An initial step of 50 °C for
2 min was used for UNG incubation, followed by 10 min at
95 °C to inactivate UNG and to activate the Taq polymerase.
Cycling conditions were a melting step at 95 °C for 15 s and
annealing–elongation at 60 °C for 1 min, for 40 cycles. The
real-time detection of double-stranded DNA allows the
construction of a dissociation curve at the end of the PCR run
by ramping the temperature of the sample from 60 °C to 95 °C,
while continuously collecting fluorescence data. The curves
of the melting profiles showed a single product and did not
reveal accumulation of primer dimers. Nontemplate and
nonamplicon controls were included for each primer pair to
check for any significant levels of contaminants, which
resulted in a difference of at least five cycles of the Ct values
compared to the template containing samples. Gel
electrophoresis of amplicons showed the correct size.
PCR amplification efficiency: In previous work, the
amplification efficiency (E) of each primer pair was
determined on a dilution series of cDNA. The values of E were
found to be close to the optimal value of 2 for all pairs [32].
For all calculations, E=2 was used.
Normalization: To correct for differences in cDNA load
between different samples, the target PCR has to be
normalized to a reference PCR. The normalization was
performed as described previously in detail [32]. Using the
TABLE 1. PRIMARY ANTIBODIES USED IN THIS STUDY
Primary antibody Dilution Source
Rabbit anti-GluR1 1:500 Upstate (Lake Placid, NY)
Rabbit anti-GluR2 1:500 BD Biosciences (Heidelberg, Germany)
Rabbit anti-GluR2/3 1:500 Chemicon (Temecula, CA)
Rabbit anti-GluR4 1:500 Chemicon
Rabbit anti-GluR6/7 1:500 Upstate
Rabbit anti-NR1 1:1 200 Tocris (Ellisville, MO)
Rabbit anti-NR2C 1:1 000 BD PharMingen (San Diego, CA)
Rabbit anti-NR3A 1:1 000 Upstate
The primary antibodies were prepared in TBS-T with 1% skimmed milk, diluted according the table. The brand name of the
antibody is also listed.
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data from all cDNA samples, for each gene the pair-wise
variation in relation to all other genes was determined as the
standard deviation of the logarithmically transformed
expression ratios. The internal gene stability measure M was
defined as the average pair-wise variation with all other
control genes. Stepwise exclusion of the gene with the highest
M value identified the combination of two constitutively
expressed genes that have the most stable expression in the
tested samples. This analysis is facilitated by the use of the
virtual basic applet GeNorm developed by Vandesompele et
al. [33]. In our model, ubiquitin C (Ubc) and TATA-box
binding protein (Tbp) were identified as the most stable genes.
Indeed, statistical analysis with Student’s t-test confirmed that
these genes are not significantly altered by diabetes. To
measure expression levels accurately, normalization to
multiple reference genes is preferred. A normalization factor
based on the expression levels of Ubc and Tbp was calculated
by using the geometric mean of the Ct. In addition,
normalization factors were calculated for Tbp-Ubc- Rho, and
so forth. The pair-wise variation (V) was calculated between
these normalization factors; a large V value means that the
added gene has a significant effect and should be included for
the final normalization factor. After the suggested cut-off
value of 0.15 by Vandesompele et al. [33], five genes were
selected as reference genes, and their transcript levels were
used to calculate the normalization factor: hypoxanthine
guanine phosphoribosyl transferase (Hprt); tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation
protein, zeta polypeptide (Ywhaz); rhodopsin (Rho); Ubc; and
Tbp.
Quantitative assessment of target gene expression: The qPCR
Ct values were converted to “absolute amounts” (C x E-Ct with
C=1010) reflecting the amount of transcript in the cDNA
sample (E-Ct). For normalization, the absolute amount of the
target gene was divided by the normalization factor [32].
Statistical analysis: Results are presented as mean±standard
error of the mean. Statistical analysis was performed using the
Student’s t-test. Significant difference was considered to be
present for p<0.05.
RESULTS
Animals: The average weight and blood glucose values for the
rats at the time of death are given in Table 3. There was a
significant weight loss in STZ-diabetic rats, compared with
age-matched controls, at one, four, and 12 weeks after the
induction of diabetes. Blood glucose levels were also
significantly increased at these time points.
The effect of age on the expression of ionotropic
glutamate receptor subunits was not the aim of this study. Gels
were not loaded with samples obtained from animals of
different age.
Effect of diabetes on protein expression of AMPA receptor
subunits: The effect of diabetes on the rat retinal protein levels
of GluR1, GluR2, GluR2/3, and GluR4 receptor subunits was
examined by western blot analysis. One week after the onset
of diabetes, the protein levels of GluR1 (Figure 1A)
significantly decreased to 66±4%, compared to the protein
levels in age-matched controls. At four and 12 weeks after the
onset of diabetes, the protein levels of GluR1 subunit
significantly increased to 139±15% and 154±14% of the
control, respectively. The protein levels of GluR2 subunit
(Figure 1B) significantly decreased to 75±8% of the control
after one week of diabetes, to 61±10% of the control after four
weeks of diabetes, and to 70±14% of the control after 12
weeks of diabetes. The protein levels of GluR2/3 subunits
increased after one, four, and 12 weeks of diabetes to
195±46%, 176±20%, and 334±116% of the control,
respectively (Figure 1C). The protein levels of GluR4 subunit
(Figure 1D) significantly decreased in one week diabetic rat
retinas to 76±8%, as compared to age-matched controls, but
the levels increased after four and 12 weeks of diabetes to
307±68% and 296±110% of the control, respectively.
Effect of diabetes on AMPA receptor subunits gene
expression: The effect of diabetes on AMPA receptor subunit-
encoding transcripts in the rat retina was analyzed by qPCR
Figure 1. Effect of diabetes on the protein levels of AMPA receptor
subunits. Total retinal extracts were obtained from rat retinas with
diabetes for one, four, and 12 weeks (black bars) and from age-
matched control rats (white bars). Extracts were assayed for (A)
GluR1, (B) GluR2, (C) GluR2/3, and (D) GluR4 subunits
immunoreactivity by western blot analysis. Representative western
blots are presented above the bars for each time point tested. The
densitometry of each band was analyzed. The results are expressed
as percentage of age-matched controls and are presented as the mean
±SEM, for the indicated number of animals. In each western blot
analysis, a reprobing for detection of α-tubulin was performed to
confirm that similar amounts of protein were applied to the gel. The
asterisk indicates a p<0.05, the double asterisk indicates a p<0.01,
and the triple asterisk indicates a p<0.001, significantly different
from control, using the two-tailed Student’s t-test.
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(Figure 2). The transcript levels of splice variants at the C-
terminal (short and long) for GluR2 and GluR4 subunits, and
the flip and flop splice variants for GluR1–4 subunits were
also evaluated. Compared to the transcript levels in the retina
of age-matched control rats, there were no significant changes
in GluR1 (Figure 2A), GluR2 (Figure 2B), GluR3 (Figure 2C),
and GluR4 (Figure 2D) subunits expression, except for GluR4
at the four weeks time point, which decreased to 68±9% of
the control.
For GluR2 and GluR4 subunits alternative splicing
occurs at the C-terminal region [34-36]. The GluR2-short
splice variant was much more abundant than the long splice
variant in all samples (Table 4). Diabetes did not cause
significant changes in the GluR2-short/-long ratio, except for
the four weeks time point (Table 4). The GluR4-long splice
variant was more abundant than the short splice variant in all
samples, but no changes were found in the diabetic groups
compared to age-matched controls (Table 4).
For all AMPA receptor subunits, so-called flip and flop
versions are present [37]. Receptors containing flip subunits
exhibit significantly slower desensitization kinetics and a
greater steady-state component in their response to glutamate
relatively to those containing flop subunits [37-40]. Overall,
no significant changes were observed in flip/flop ratio due to
diabetes (Table 4).
Figure 2. Effect of diabetes on the transcript levels of AMPA receptor
subunits. Total RNA was isolated from rat retinas with one, four and
12 weeks of diabetes (black bars) and from rat retinas of age-matched
controls (white bars). The transcript levels of (A) GluR1, (B) GluR2,
(C) GluR3, (D) GluR4 subunits were analyzed by qPCR. The results
represent the normalized expression levels for each subunit, as
explained in Methods, and are presented as the mean±SEM, for the
indicated number of animals. The asterisk indicates a p<0.05,
significantly different from control, using the two-tailed Student’s t-
test.
TABLE 3. WEIGHT AND BLOOD GLUCOSE LEVELS AT TIME OF DEATH.
Group n Weight (g) Blood glucose (mg/dl)
Control 1 week 25 254.1±7.6 104.6±3.4
Diabetic 1 week 24 189.9±9.9*** 401.7±25.5***
Control 4 weeks 33 341.9±11.8 91.1±1.7
Diabetic 4 weeks 25 225.8±7.8*** 437.9±11.9***
Control 12 weeks 36 363.9±14.9 96.7±3.9
Diabetic 12 weeks 30 237.3±11.2*** 479.1±8.8***
Animals were weighed and blood glucose levels were measured before sacrifice. The triple asterisk indicates a p<0.001,
significantly different from control, using the two-tailed Student’s t-test.
TABLE 4. RATIOS OF THE FLIP:FLOP AND SHORT:LONG SPLICE VARIANTS FOR AMPA RECEPTOR SUBUNITS
AMPA receptor 
splice variants
1 week                                           4 weeks                                        12 weeks
Control Diabetic Control Diabetic Control Diabetic
GluR1 flip:flop 1.19±0.05 1.24±0.04 1.08±0.02 1.06±0.02 1.30±0.05 1.08±0.03**
GluR2-short:long 37.7±5.0 40.5±3.4 33.6±1.5 54.2±9.1** 37.6±2.2 43.9±2.3
GluR2 flip:flop 2.69±0.23 2.43±0.13 2.54±0.24 2.71±0.11 2.49±0.12 2.85±0.16
GluR3 flip:flop 1.01±0.06 1.01±0.05 1.13±0.09 1.14±0.10 1.11±0.08 1.03±0.05
GluR4-short:long 0.72±0.08 0.68±0.04 0.61±0.04 0.61±0.02 0.75±0.05 0.71±0.05
GluR4 flip:flop 0.40±0.04 0.44±0.03 0.51±0.06 0.50±0.08 0.54±0.07 0.63±0.08
The ratio is calculated using the normalized expression levels for each isoform for each animal and expressed as the mean±SEM.
The double asterisk indicates a p<0.01, and the triple asterisk indicates a p<0.001, significantly different from control, using
the two-tailed Student’s t-test.
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Effect of diabetes on protein and gene expression of kainate
receptor subunits: One week after the onset of diabetes, there
were no changes in the protein levels of GluR6/7 subunits
(Figure 3A). After four weeks of diabetes, the protein levels
of GluR6/7 significantly decreased to 77±10%, when
compared to age-matched controls. However, after 12 weeks
of diabetes, the protein levels of GluR6/7 subunits
significantly increased to 148±18% of the control.
The transcript levels of GluR7 subunit (Figure 3B) were
unchanged in the rat retinas, one week after the induction of
diabetes, as compared to age-matched controls. However, the
transcript levels of this subunit significantly decreased to
69±10% of the control after four weeks of diabetes, and
increased after 12 weeks to 126±10% of the control.
The transcript levels of GluR5 and GluR6 subunits were
below the detection level (data not shown).
Effect of diabetes on protein and gene expression of NMDA
receptor subunits: Diabetes induced changes in the NR1
subunit protein levels in the retina (Figure 4A). In retinas from
rats who had diabetes one week, the protein expression levels
of NR1 subunit significantly decreased to 41±7% of the
control. However, after four weeks of diabetes, the protein
levels of NR1 subunit significantly increased to 186±23% of
the control, and 12 weeks after the onset of diabetes, the
protein levels of NR1 subunit decreased to 74±3% of the
control.
The protein expression of NR2C (Figure 4B) was not
significantly changed in retinas of rats with diabetes for one
week, compared to age-matched controls; it significantly
increased to 132±10% of the control after four weeks of
diabetes. In rats who had 12 weeks of diabetes, the protein
levels of NR2C subunit were similar to the control. The
protein expression levels of NR3A subunit (Figure 4C)
increased in the retinas of rats after one week of diabetes to
170±16% of the control, to 153±22% of the control after four
weeks of diabetes, and to 142±19% of the control after 12
weeks of diabetes.
The transcript levels of NR1 subunit (Figure 5A) were
upregulated after one and four weeks of diabetes, as compared
to age-matched controls, but were unchanged after 12 weeks.
The transcript levels of NR2C (Figure 5B) and NR3A (Figure
5C) subunits remained unchanged at the three time points
investigated.
DISCUSSION
There is evidence to support the involvement of glutamate in
the pathogenesis of DR. In the retina of diabetic animals, the
metabolism of glutamate is impaired [24,25] and the release of
D-aspartate is increased [28]. Furthermore, in cultured retinal
neural cells we previously found that elevated glucose
changes the content of AMPA and kainate glutamate receptor
subunits [29]. These findings led us to hypothesize that
ionotropic glutamate receptor subunits expression is changed
in the retina of diabetic rats. Changes in subunit composition
may alter glutamate receptor properties, therefore affecting
retinal neurotransmission and consequently vision. Thus, the
main purpose of this study was to investigate whether diabetes
changes the expression of ionotropic glutamate receptor
subunits in the retina, and to determine if changes at the
Figure 3. Effect of diabetes on kainate receptor subunits expression.
Total protein extracts (A) and total RNA extracts (B) were prepared
from rat retinas with one, four, and 12 weeks diabetic rat retinas
(black bars) and from age-matched controls (white bars). A: Total
retinal extracts were assayed for GluR6/7 subunits immunoreactivity
by western blot analysis. Representative western blots are presented
above the graph. The densitometry of each band was analyzed. The
results are expressed as percentage of age-matched controls and are
presented as the mean±SEM, for the indicated number of animals. In
each western blot analysis, a reprobing for detection of α-tubulin was
performed to confirm that similar amounts of protein were applied
to the gel. The asterisk indicates a p<0.05, significantly different
from control, using the two-tailed Student’s t-test. B: The transcript
levels of GluR7 subunit were analyzed by qPCR. The results
represent the normalized expression levels for GluR7 subunit, as
explained in Methods, and are presented as the mean±SEM, for the
indicated number of animals. The asterisk indicates a p<0.05,
significantly different from control, using the two-tailed Student’s t-
test.
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protein level were associated with changes at the gene
expression level.
Our results demonstrate that diabetes does alter the
expression of ionotropic glutamate receptor subunits in the
retina, but mainly at the protein level. Of particular interest is
the significant downregulation of GluR2 subunit protein
expression, found at all three time points studied. AMPA
receptors are usually less permeable to calcium than the
NMDA receptor. However, AMPA receptors lacking the
GluR2 subunit are calcium-permeable [41-43]. The
downregulation of GluR2 subunit may serve as a molecular
switch leading to the formation of calcium-permeable AMPA
receptors, which may enhance the toxicity of endogenous
glutamate following a neurologic insult [44]. Previously, it
was reported that the calcium-binding proteins, calbindin and
parvalbumin, are increased in the retina of STZ-induced
diabetic rats, probably to increase the buffering capacity of
retinal cells to maintain the calcium homeostasis and protect
them against the damaging effects of excessive calcium influx
during overstimulation of ionotropic glutamate receptors
[31].
Figure 4. Effect of diabetes on the protein levels of NMDA receptor
subunits. Total retinal extracts were prepared from rat retinas with
one, four, and 12 weeks of diabetes (black bars) and from age-
matched control rats (white bars). Extracts were assayed for (A) NR1,
(B) NR2C, and (C) NR3A subunits immunoreactivity by western
blot analysis. Representative western blots are presented above the
graphs for each time point tested. The densitometry of each band was
analyzed. The results are expressed as percentage of age-matched
controls and are presented as the mean±SEM, for the indicated
number of animals. In each western blot analysis, a reprobing for
detection of α-tubulin was performed to confirm that similar amounts
of protein were applied to the gel. The asterisk indicates a p<0.05,
the double asterisk indicates a p<0.01, and the triple asterisk indicates
a p<0.001, significantly different from control, using the two-tailed
Student’s t-test.
We have also found an increase in GluR2/3 subunits,
suggesting that GluR3 subunit is upregulated in diabetic rat
retinas. The lack of a suitable anti-GluR3 subunit antibody has
prevented us from testing this possibility in a more direct way.
Previously, it was demonstrated that GluR2/3 subunits are
more abundant in the retinas of rats with diabetes four four
and 16 weeks in ganglion, amacrine and bipolar cells as well
as in the inner and outer plexiform layers [31]. The same work
reported increased levels of NR1 subunit in the retinas of rats
who had diabetes for four or 16 weeks. In our case, we found
that NR1 subunit protein levels were not elevated throughout
the complete course of diabetes; NR1 subunit protein levels
were downregulated at one week, upregulated at four weeks,
and downregulated at 12 weeks. This is particularly relevant
since most of the studies deal with only one time point of
diabetes and, as we found, the diabetic rat retina is not a static
tissue.
Another important finding of this study is the increase in
NR3A subunit in the retinas of diabetic animals. In vitro
studies indicate that NR3A is a modulatory subunit that can
alter NMDA receptor activity and function [45-48].
Electrophysiological studies have shown that the NR3A
subunit can co-assemble with NR1 and NR2A to form
functional NMDA receptors with decreased NMDA receptor
activity and decreased Ca2+ flux [47,48]; mice lacking the
NR3A subunit show enhanced NMDA receptor activity [46].
There is no data demonstrating that NR3A preferentially
assembles with certain NMDA receptor subunits. However,
Figure 5. Effect of diabetes on the transcript levels of NMDA
receptor subunits. Total RNA extracts were prepared from rat retinas
with one, four, and 12 weeks of diabetes (black bars) and from age-
matched controls (white bars), and the transcript levels of (A) NR1,
(B) NR2C, and (C) NR3A subunits were analyzed by qPCR. The
results represent the normalized expression levels for each subunit,
as explained in Methods, and are presented as the mean±SEM, for
the indicated number of animals. The asterisk indicates a p<0.05,
significantly different from control, using the two-tailed Student’s t-
test.
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in NR3A-overexpressing transgenic mice, NR3A is
incorporated into at least a subset of NMDA receptors,
mitigating their responses in hippocampal neurons [49].
Considering its suppressive effects on NMDA receptors,
NR3A has been suggested to act as a neuroprotective
modulator. NR3A subunit has been found in the inner retina
from the rodent retina from an early postnatal age and
persisting into adulthood [50]. The same study reported that
NR3A may modulate NMDA receptor-mediated calcium
influx in retinal ganglion cells and amacrine cells, decreasing
the intracellular calcium changes concentration. We have
previously reported an increase in glutamate release during
diabetes [28], which may lead to glutamate excitotoxicity. The
increase in NR3A subunit in diabetic rat retinas may be a
compensatory mechanism to prevent calcium overload.
Previously, in cultured retinal neural cells, we found that
the protein levels of GluR1 and GluR6/7 subunits decrease
and GluR2 and KA2 subunits increase [29]. Therefore, the
data obtained in this work does not completely fit with the in
vitro study, where we investigated only one time point of
elevated glucose incubation (seven days). Also, in diabetic
human postmortem retinas we have found that GluR2 and
NR1 subunits are altered, mainly at the plexiform layers and
ganglion cell layer [30]. Thus, the main conclusion of this
work is that hyperglycemia induces alterations in ionotropic
glutamate receptors, which may have consequences in
receptor function and eventually in retinal cell viability.
Our results also show that in general there was no
correlation between the results found for protein and mRNA
expression levels, indicating that the changes observed in the
ionotropic glutamate receptor subunits at the protein level are
not the result of changes at the transcript level. In this work,
the data are derived from the total retina, giving an average of
the expression level of a particular ionotropic glutamate
receptor subunit in the whole retina, losing the cell-to-cell
variation. The level of expression of each glutamate receptor
subunit is determined, at any particular time, by the balance
of the rates of gene transcription, mRNA translation, mRNA
degradation, and protein degradation. The most significant
changes are observed at the protein level, which suggests that
diabetes changes the ratio of protein synthesis as well as
degradation. Recently, it was reported that genes for protein
synthesis are upregulated in the retina of diabetic mice [51].
At least in the STZ-induced diabetic rat model, the
presumption that changes at the mRNA expression are
translated to similar changes at the protein level should not be
followed.
This work also addressed whether diabetes induces
alterations in the splicing mechanisms encoding for different
C-terminal variants of GluR2 and GluR4 and on the splicing
machinery of AMPA receptor subunits encoding for flip and
flop isoforms. In control retinas, the short splice variant of
GluR2 is more abundant than the long splice variant, and
GluR4-long is also more abundant than GluR4-short, in
accordance with previous reports [32]. Our data did not
provide clear evidence for profound alterations in either the
ratio of the long and short variants or the ratio of flip and flop
splice variants, suggesting that the splicing mechanisms
leading to these isoforms are not altered by diabetes.
In conclusion, the observed changes in ionotropic
glutamate receptor subunits content show that diabetes affects
a main component of the excitatory neurotransmission,
suggesting potential alterations in synaptic communication
throughout the retina, which may contribute to color vision
defects or loss of contrast sensitivity [5,52]. Also, the
expression of ionotropic glutamate receptors with abnormal
subunit composition may cause neurons to become more
vulnerable to excitotoxic stress. It remains to be determined
whether these changes contribute to the subsequent
neurodegeneration found in diabetic retinas.
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